201 related articles for article (PubMed ID: 38132447)
1. Integrative Analysis of the Role of
Liu T; Du J; Cheng X; Wei J
Curr Issues Mol Biol; 2023 Nov; 45(12):9606-9633. PubMed ID: 38132447
[TBL] [Abstract][Full Text] [Related]
2. p53 in breast cancer subtypes and new insights into response to chemotherapy.
Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of
Monti P; Menichini P; Speciale A; Cutrona G; Fais F; Taiana E; Neri A; Bomben R; Gentile M; Gattei V; Ferrarini M; Morabito F; Fronza G
Front Oncol; 2020; 10():593383. PubMed ID: 33194757
[TBL] [Abstract][Full Text] [Related]
4. Mutations in TP53 or DNA damage repair genes define poor prognostic subgroups in primary prostate cancer.
Nientiedt C; Budczies J; Endris V; Kirchner M; Schwab C; Jurcic C; Behnisch R; Hoveida S; Lantwin P; Kaczorowski A; Geisler C; Dieffenbacher S; Falkenbach F; Franke D; Görtz M; Heller M; Himmelsbach R; Pecqueux C; Rath M; Reimold P; Schütz V; Simunovic I; Walter E; Hofer L; Gasch C; Schönberg G; Pursche L; Hatiboglu G; Nyarangi-Dix J; Sültmann H; Zschäbitz S; Koerber SA; Jäger D; Debus J; Duensing A; Schirmacher P; Hohenfellner M; Stenzinger A; Duensing S
Urol Oncol; 2022 Jan; 40(1):8.e11-8.e18. PubMed ID: 34325986
[TBL] [Abstract][Full Text] [Related]
5. Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
McCubrey JA; Yang LV; Abrams SL; Steelman LS; Follo MY; Cocco L; Ratti S; Martelli AM; Augello G; Cervello M
Cells; 2022 Jul; 11(14):. PubMed ID: 35883598
[TBL] [Abstract][Full Text] [Related]
6. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
[TBL] [Abstract][Full Text] [Related]
7. RNA interference-mediated silencing of the p53 tumor-suppressor protein drastically increases apoptosis after inhibition of endogenous fatty acid metabolism in breast cancer cells.
Menendez JA; Lupu R
Int J Mol Med; 2005 Jan; 15(1):33-40. PubMed ID: 15583825
[TBL] [Abstract][Full Text] [Related]
8. [TP53 mutations and molecular epidemiology].
Otsuka K; Ishioka C
Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneous mutational profile and prognosis conferred by TP53 mutations in appendiceal mucinous neoplasms.
Zhu X; Salhab M; Tomaszewicz K; Meng X; Mathew C; Bathini V; Switzer B; Walter O; Cosar EF; Wang X; Lambert LA; Hutchinson LM
Hum Pathol; 2019 Mar; 85():260-269. PubMed ID: 30458197
[TBL] [Abstract][Full Text] [Related]
10. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
El Baroudi M; Machiels JP; Schmitz S
Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
[TBL] [Abstract][Full Text] [Related]
11. Role of p53 Gene in Breast Cancer: Focus on Mutation Spectrum and Therapeutic Strategies.
Kaur RP; Vasudeva K; Kumar R; Munshi A
Curr Pharm Des; 2018; 24(30):3566-3575. PubMed ID: 30255744
[TBL] [Abstract][Full Text] [Related]
12. DNA sequence profile of TP53 gene mutations in childhood B-cell non-Hodgkin's lymphomas: prognostic implications.
Klumb CE; Furtado DR; de Resende LM; Carriço MK; Coelho AM; de Meis E; Maia RC; Rumjanek FD
Eur J Haematol; 2003 Aug; 71(2):81-90. PubMed ID: 12890146
[TBL] [Abstract][Full Text] [Related]
13. Cancer type-dependent correlations between TP53 mutations and antitumor immunity.
Li L; Li M; Wang X
DNA Repair (Amst); 2020 Apr; 88():102785. PubMed ID: 32007736
[TBL] [Abstract][Full Text] [Related]
14. Integrated Analysis of TP53 Gene and Pathway Alterations in The Cancer Genome Atlas.
Donehower LA; Soussi T; Korkut A; Liu Y; Schultz A; Cardenas M; Li X; Babur O; Hsu TK; Lichtarge O; Weinstein JN; Akbani R; Wheeler DA
Cell Rep; 2019 Jul; 28(5):1370-1384.e5. PubMed ID: 31365877
[TBL] [Abstract][Full Text] [Related]
15. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM
Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573
[TBL] [Abstract][Full Text] [Related]
16. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line.
Supino R; Perego P; Gatti L; Caserini C; Leonetti C; Colantuono M; Zuco V; Carenini N; Zupi G; Zunino F
Eur J Cancer; 2001 Nov; 37(17):2247-56. PubMed ID: 11677115
[TBL] [Abstract][Full Text] [Related]
17. miR129-1 regulates protein phosphatase 1D protein expression under hypoxic conditions in non-small cell lung cancer cells harboring a TP53 mutation.
Yin HL; Xu HW; Lin QY
Oncol Lett; 2020 Sep; 20(3):2239-2247. PubMed ID: 32782541
[TBL] [Abstract][Full Text] [Related]
18. Should mutant TP53 be targeted for cancer therapy?
Wang Z; Strasser A; Kelly GL
Cell Death Differ; 2022 May; 29(5):911-920. PubMed ID: 35332311
[TBL] [Abstract][Full Text] [Related]
19. Maintaining genetic stability through TP53 mediated checkpoint control.
Wahl GM; Linke SP; Paulson TG; Huang LC
Cancer Surv; 1997; 29():183-219. PubMed ID: 9338102
[TBL] [Abstract][Full Text] [Related]
20. TP53 mutations, expression and interaction networks in human cancers.
Wang X; Sun Q
Oncotarget; 2017 Jan; 8(1):624-643. PubMed ID: 27880943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]